By Aditi Mishra
The Supreme Court of India has directed the Central Government to set up a committee and analyze unethical pharma practices exercised by pharmaceutical companies, with special focus on incentives and other special benefits offered to doctors. The committee will review the current framework and make amendments to improve accountability, monitoring and ethical enforcement. Unethical pharmaceutical practices can affect prescription choices, drug affordability, and can cost risk to public health.
Pharmaceutical companies often offer hampers, gifts, sponsored travel, and hospitality to maintain effective relationships with doctors to promote their drug marketing and help in strategic promotions. These practices have raised a big question about public health: whether commercial perks can influence doctors’ prescription decisions that are meant to be entirely based on an individual's medical needs.
From these practices, doctors’ choice of medicines may get influenced by commercial benefits, and patients may get prescribed a specific brand instead of affordable medicines that already exist in the market. These practices can increase treatment costs and oblige patients to unnecessary expensive medications and can expose patients to potential drug allergic reactions or inadequate antibiotic use.
Although receiving promotional perks or hampers does not necessarily mean that a doctor’s prescription will be replaced by a specific pharma company drug brand, the bigger concern is whether these benefits compromise public purchasing power and affect authentic clinical judgement.
Also See: Cheap Medicines Prevented Migraine as Well as Expensive Ones
India is set to regulate and make amends in pharmaceuticals marketing under the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) 2024. This act will set out ethical standards for pharmaceutical companies while they promote their drug brands or medicines to doctors, keeping special focus on public health and wellness, but the bigger concern is whether the existing legal framework has sufficient backing and an effective implementation mechanism to prevent pharma companies from unethical marketing.
The Supreme Court has asked the Centre to examine the legal void and decide if the discussed amends, stricter measures are actually required.
The review is still in progress, which means no new rules have been implemented yet.
What Happens Next in Supreme Court’s Pharma Freebies Case?
The Supreme Court has instructed the centre to set up a committee, to thoroughly review the unethical marketing strategies used by big pharma companies and recommend effective measures to address them. The Supreme Court has given a deadline to form the committee within 2 weeks if not already formed and to submit its recommendations within two weeks after its first meeting. The committee will review the existing legal framework, including UCPMP, and decide whether stricter legal rules and regulations should be laid to prevent unethical offerings to doctors and medical professionals. The Centre must then take the recommendation into consideration and issue a decision.
The discussion will reopen before the court on January 29, 2027, when the court will review the Centre’s recommendations. The outcome will determine if the Pharmaceuticals company should continue with their practices or if necessary amendments will be made.
(Rh/AM)
